Pancreatic Cancer Research

ResearcherUniversity of North Carolina at Chapel HillActive in the last 2 years

Jen Jen Yeh

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2542-6211; OpenAlex author ID A5065098287, A5089529833; NIH RePORTER profile ID 9084260. Sources: ClinicalTrials.gov.

Their work

Papers
54 (first author 3, last author 17)
Trials
1 (principal investigator on 1)
Grants
8
Labs led
1
Collaborators
220
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 3 papers · 2014: 6 papers, 2 grants · 2015: 1 paper · 2016: 3 papers · 2017: 3 papers · 2018: 7 papers · 2019: 1 grant · 2020: 5 papers · 2021: 3 papers, 1 grant · 2022: 1 paper · 2023: 1 paper · 2024: 8 papers · 2025: 3 papers · 2026: 7 papers, 1 trial, 3 grants

Papers 50 of 54

  1. Characterizing pancreatic cancer-associated fibroblast heterogeneity in vascular microphysiological systems. Co-author DOI 10.1007/s10456-026-10061-9↗
  2. Human pancreatic progenitor organoids define genetic and epigenetic barriers to early PDAC transformation. Co-author DOI 10.1016/j.devcel.2026.04.012↗
  3. Limitations of GATA6 and CK5 as surrogate markers for molecular subtyping in pancreatic cancer. Last author DOI 10.1016/j.hpb.2026.08.001↗
  4. Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial. Co-author DOI 10.1038/s43018-026-01165-8↗
  5. Advances in RAS Therapeutics for Pancreatic Cancer. First author DOI 10.1056/nejme2600517↗
  6. Context-specific genetic interaction mapping reveals combinatorial KRAS/FGFR dependence in pancreatic cancer Co-author DOI 10.64898/2026.09.24.754062↗
  7. NEIL2 regulates RNA polymerase II dynamics to suppress transcription–replication conflicts in pancreatic cancer Co-author DOI 10.64898/2026.10.19.760262↗
  8. New Onset Diabetes in Pancreatic Adenocarcinoma Does Not Correlate With Molecular Subtype. Last author DOI 10.1002/jso.28044↗
  9. PCSK9 drives sterol-dependent metastatic organ choice in pancreatic cancer. Co-author DOI 10.1038/s41586-025-09017-8↗
  10. Tumor-Intrinsic Kinome Landscape of Pancreatic Cancer Reveals New Therapeutic Approaches. Last author DOI 10.1158/2159-8290.cd-23-1480↗
  11. Myofibroblastic cancer-associated fibroblast subtype heterogeneity in pancreatic cancer. Last author DOI 10.1002/jso.27582↗
  12. Purity Independent Subtyping of Tumors (PurIST) Pancreatic Cancer Classifier: Analytic Validation of a 16-RNA Expression Signature Distinguishing Basal and Cla… Co-author DOI 10.1016/j.jmoldx.2024.07.002↗
  13. Updates in Molecular Profiling of Pancreatic Ductal Adenocarcinoma. First author DOI 10.1016/j.suc.2024.04.001↗
  14. Tumor-intrinsic and Cancer-associated Fibroblast Subtypes Independently Predict Outcomes in Pancreatic Cancer. Last author DOI 10.1097/sla.0000000000006416↗
  15. nSMase2-mediated exosome secretion shapes the tumor microenvironment to immunologically support pancreatic cancer Co-author DOI 10.1101/2024.09.23.614610↗
  16. Future of Dendritic Cell-Based Approaches in Pancreatic Cancer. First author DOI 10.1200/jco.24.00846↗
  17. First-in-Class Humanized Antibody against Alternatively Spliced Tissue Factor Augments Anti-Metastatic Efficacy of Chemotherapy in a Preclinical Model of Pancr… Co-author DOI 10.3390/ijms25052580↗
  18. Kinome state is predictive of cell viability in pancreatic cancer tumor and cancer-associated fibroblast cell lines. Co-author DOI 10.7717/peerj.17797↗
  19. Open-source curation of a pancreatic ductal adenocarcinoma gene expression analysis platform (pdacR) supports a two-subtype model. Co-author DOI 10.1038/s42003-023-04461-6↗
  20. Truncated O-Glycan-Bearing MUC16 Enhances Pancreatic Cancer Cells Aggressiveness via α4β1 Integrin Complexes and FAK Signaling. Co-author DOI 10.3390/ijms23105459↗
  21. Pathology and Molecular Characteristics of Pancreatic Cancer. Last author DOI 10.1016/j.soc.2021.06.003↗
  22. Isoforms of MUC16 activate oncogenic signaling through EGF receptors to enhance the progression of pancreatic cancer. Co-author DOI 10.1016/j.ymthe.2020.12.029↗
  23. The PDAC Extracellular Matrix: A Review of the ECM Protein Composition, Tumor Cell Interaction, and Therapeutic Strategies. Last author DOI 10.3389/fonc.2021.751311↗
  24. Enhanced Efficacy of Combination of Gemcitabine and Phosphatidylserine-Targeted Nanovesicles against Pancreatic Cancer. Co-author DOI 10.1016/j.ymthe.2020.05.013↗
  25. Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-19-1467↗
  26. B cell-Derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-19-0349↗
  27. Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy. Last author DOI 10.1172/jci.insight.129905↗
  28. Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix. Co-author DOI 10.1172/jci136760↗
  29. Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer. Last author DOI 10.1007/s00280-018-3570-3↗
  30. Altered exocrine function can drive adipose wasting in early pancreatic cancer. Co-author DOI 10.1038/s41586-018-0235-7↗
  31. Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Co-author DOI 10.1158/1078-0432.ccr-17-2994↗
  32. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Co-author DOI 10.1158/2159-8290.cd-18-0275↗
  33. Application of Integrated Drug Screening/Kinome Analysis to Identify Inhibitors of Gemcitabine-Resistant Pancreatic Cancer Cell Growth. Co-author DOI 10.1177/2472555218773045↗
  34. Stromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic Adenocarcinoma. Co-author DOI 10.1200/po.17.00121↗
  35. The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. Co-author DOI 10.1371/journal.pone.0202272↗
  36. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ccell.2017.07.007↗
  37. Genetic and pharmacological inhibition of TTK impairs pancreatic cancer cell line growth by inducing lethal chromosomal instability. Last author DOI 10.1371/journal.pone.0174863↗
  38. Hexokinase 2 promotes tumor growth and metastasis by regulating lactate production in pancreatic cancer. Last author DOI 10.18632/oncotarget.9760↗
  39. Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. Co-author DOI 10.1016/j.ccell.2015.11.011↗
  40. Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma. Last author DOI 10.1073/pnas.1600421113↗
  41. Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts. Last author DOI 10.1371/journal.pone.0147113↗
  42. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Last author DOI 10.1038/ng.3398↗
  43. Micropallet arrays for the capture, isolation and culture of circulating tumor cells from whole blood of mice engrafted with primary human pancreatic adenocarc… Co-author DOI 10.1016/j.bios.2013.11.019↗
  44. Measurement of protein kinase B activity in single primary human pancreatic cancer cells. Co-author DOI 10.1021/ac500616q↗
  45. Palladin promotes invasion of pancreatic cancer cells by enhancing invadopodia formation in cancer-associated fibroblasts. Co-author DOI 10.1038/onc.2013.68↗
  46. Value of intraoperative neck margin analysis during Whipple for pancreatic adenocarcinoma: a multicenter analysis of 1399 patients. Co-author DOI 10.1097/sla.0000000000000890↗
  47. Response to MLN8237 in pancreatic cancer is not dependent on RalA phosphorylation. Last author DOI 10.1158/1535-7163.mct-12-1232↗
  48. Circulating tumor cells as a biomarker of response to treatment in patient-derived xenograft mouse models of pancreatic adenocarcinoma. Last author DOI 10.1371/journal.pone.0089474↗
  49. Isolation and in vitro culture of rare cancer stem cells from patient-derived xenografts of pancreatic ductal adenocarcinoma. Co-author DOI 10.1021/ac401165s↗
  50. Modular microsystem for the isolation, enumeration, and phenotyping of circulating tumor cells in patients with pancreatic cancer. Co-author DOI 10.1021/ac401720k↗

Trials 1

  1. SURGIMEDIA: Utilization of Multimedia for Enhanced Surgical Consent Principal investigator NCT07494994↗

Grants 8

  1. SToP Cancer SPORE: Administrative Core A P50CA257911↗
  2. Targeted EGFR for basal subtype pancreatic cancer R01CA288145↗
  3. Integrating tumor and stroma to understand and predict treatment response U01CA274298↗
  4. Tumor Subtypes and Therapy Response in Pancreatic Cancer R01CA199064↗
  5. The adaptive kinome in pancreatic cancer R01CA193650↗
  6. Targeting Ras-Ral GEF-Ral Effector Signaling for Pancreatic Cancer Treatment R01CA140424↗
  7. Nanoscale Metal-organic Frameworks for Imaging and Therapy of Pancreatic Cancer U01CA151455↗
  8. LEAD Project Grant: Jen Jen Yeh AWARD lustgarten:na-jen-jen-yeh-lead-project-grant-jen-jen-yeh

Closest collaborators

The 25 strongest of 220 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Naim U. Rashid · 11 shared papers, 1 shared grant, 2015–2026 · strength 2.66
  2. Gary L. Johnson · 4 shared papers, 3 shared grants, 2018–2026 · strength 2.60
  3. Channing J. Der · 4 shared papers, 1 shared grant, 2014–2026 · strength 1.46
  4. Susan Tsai · 2 shared grants, 2021–2026 · strength 1.38
  5. Alina Cornelia Iuga · 2 shared papers, 1 shared grant, 2025–2026 · strength 1.15
  6. Joseph F. Kearney · 5 shared papers, 2021–2025 · strength 1.07
  7. Jaewon James Lee · 3 shared papers, 2024–2026 · strength 0.93
  8. ALBERT Sidney BALDWIN · 1 shared paper, 1 shared grant, 2013–2026 · strength 0.71
  9. Michael R Kosorok · 1 shared grant, 2026 · strength 0.67
  10. Gianpietro Dotti · 1 shared grant, 2026 · strength 0.67
  11. Jonathan S. Serody · 1 shared grant, 2026 · strength 0.67
  12. Sandra Zarmer · 3 shared papers, 2024–2026 · strength 0.65
  13. Hannah E. Trembath · 3 shared papers, 2024–2025 · strength 0.62
  14. Lee M. Graves · 3 shared papers, 1 shared grant, 2017–2021 · strength 0.62
  15. Richard A. Moffitt · 7 shared papers, 2014–2023 · strength 0.61
  16. Andrew J. Aguirre · 3 shared papers, 2023–2026 · strength 0.58
  17. Michael Anthony Hollingsworth · 6 shared papers, 2012–2022 · strength 0.49
  18. Ashwin Somasundaram · 1 shared paper, 2024 · strength 0.46
  19. James M. Cleary · 2 shared papers, 2026 · strength 0.40
  20. Shawn M. Gomez · 2 shared papers, 2024–2025 · strength 0.39
  21. David W. Dawson · 2 shared papers, 2024–2026 · strength 0.38
  22. Michael Haas · 2 shared papers, 2025 · strength 0.37
  23. Steffen Ormanns · 2 shared papers, 2025 · strength 0.37
  24. Lisa Miller‐Phillips · 2 shared papers, 2025 · strength 0.37
  25. Volker Heinemann · 2 shared papers, 2025 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.